ArticleFrontiers in molecular biosciences2026
Analysis of peripheral blood T-cell levels for predicting immunotherapy response sensitivity in squamous cell carcinoma of the head and neck.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the correlation between peripheral blood immune cell subsets and pathological response to neoadjuvant therapy in locally advanced head and neck squamous cell carcinoma (HNSCC), and to evaluate their predictive value. Methods: A total of 57 patients with locally advanced HNSCC were retrospectively enrolled. Patients were divided into a chemotherapy group (TPF regimen, n = 25) and a chemoimmunotherapy group (TPK regimen, n = 32). Peripheral blood percentages and absolute counts of CD4 Results: In the chemoimmunotherapy group, primary tumor and dual pCR rates were 75.0% (24/32) and 37.0% (10/27), respectively; subsequent surgery was significantly reduced. Post-chemoimmunotherapy, CD3 Conclusion: Chemoimmunotherapy can induce a significant decrease in peripheral blood CD28
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.